You’re using a public version of DrugPatentWatch with 1 free search available | Register to unlock more free searches. CREATE FREE ACCOUNT

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKesson
Merck
Colorcon
Baxter
Express Scripts

Last Updated: September 25, 2023

Investigational Drug Information for Clazakizumab


✉ Email this page to a colleague

« Back to Dashboard


What is the drug development status for Clazakizumab?

Clazakizumab is an investigational drug.

There have been 16 clinical trials for Clazakizumab. The most recent clinical trial was a Phase 2 trial, which was initiated on October 14th 2019.

The most common disease conditions in clinical trials are COVID-19, Infection, and Kidney Failure, Chronic. The leading clinical trial sponsors are CSL Behring, Vitaeris INC, and NYU Langone Health.

There are four US patents protecting this investigational drug and thirty-three international patents.

Recent Clinical Trials for Clazakizumab
TitleSponsorPhase
Improving Physical Function in Older Adults Using an Anti-inflammation Drug: The RIGHT StudyCSL BehringPhase 2
Improving Physical Function in Older Adults Using an Anti-inflammation Drug: The RIGHT StudyAnne B. NewmanPhase 2
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing DialysisCSL BehringPhase 2/Phase 3

See all Clazakizumab clinical trials

Clinical Trial Summary for Clazakizumab

Top disease conditions for Clazakizumab
Top clinical trial sponsors for Clazakizumab

See all Clazakizumab clinical trials

US Patents for Clazakizumab

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Clazakizumab ⤷  Try a Trial Soluble C5aR antagonists ChemoCentryx, Inc. (Mountain View, CA) ⤷  Try a Trial
Clazakizumab ⤷  Try a Trial Cholestosome vesicles for incorporation of molecules into chylomicrons THERASYN SENSORS, INC. (Eggertsville, NY) ⤷  Try a Trial
Clazakizumab ⤷  Try a Trial Soluble C5aR antagonists ChemoCentryx, Inc. (Mountain View, CA) ⤷  Try a Trial
Clazakizumab ⤷  Try a Trial Binding-triggered transcriptional switches and methods of use thereof The Regents of the University of California (Oakland, CA) ⤷  Try a Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Clazakizumab

Drugname Country Document Number Estimated Expiration Related US Patent
Clazakizumab Argentina AR108097 2036-04-04 ⤷  Try a Trial
Clazakizumab Australia AU2017246228 2036-04-04 ⤷  Try a Trial
Clazakizumab Brazil BR112018070214 2036-04-04 ⤷  Try a Trial
Clazakizumab Canada CA3019137 2036-04-04 ⤷  Try a Trial
Clazakizumab Chile CL2018002803 2036-04-04 ⤷  Try a Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKesson
Merck
Colorcon
Baxter
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.